Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $295.7 million.

  • Madrigal Pharmaceuticals' Cash & Equivalents rose 2707.96% to $295.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.7 million, marking a year-over-year increase of 2707.96%. This contributed to the annual value of $100.0 million for FY2024, which is 10.41% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Cash & Equivalents of $295.7 million as of Q3 2025, which was up 2707.96% from $186.2 million recorded in Q2 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Cash & Equivalents peaked at $622.5 million during Q1 2024, and registered a low of $33.5 million during Q2 2021.
  • In the last 5 years, Madrigal Pharmaceuticals' Cash & Equivalents had a median value of $99.9 million in 2023 and averaged $164.1 million.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Cash & Equivalents soared by 81413.88% in 2022 and then crashed by 7049.94% in 2025.
  • Madrigal Pharmaceuticals' Cash & Equivalents (Quarter) stood at $36.3 million in 2021, then soared by 814.14% to $331.5 million in 2022, then crashed by 69.86% to $99.9 million in 2023, then increased by 0.1% to $100.0 million in 2024, then surged by 195.64% to $295.7 million in 2025.
  • Its Cash & Equivalents stands at $295.7 million for Q3 2025, versus $186.2 million for Q2 2025 and $183.6 million for Q1 2025.